Abstract
This chapter is about persistence of ROP disease after laser coagulation or anti-VEGF. What to do? In addition, treatment algorithms for ROP 3+ disease for treatment centers as well as for non-treatment centers are displayed and explained.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register. Br J Ophthalmol. 2016;100(12):1656–61.
Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123(9):1845–55.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Spandau, U., Kim, S.J. (2019). Persistence of ROP Disease After Laser Coagulation or Anti-VEGF: What to Do?. In: Pediatric Retinal Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-13701-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-13701-4_20
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13700-7
Online ISBN: 978-3-030-13701-4
eBook Packages: MedicineMedicine (R0)